CoChat

Cost of Chronic Hepatitis B Infection in the United States

Lee, Todd A., Veenstra, David L., Iloeje, Uchenna H., Sullivan, Sean D. · 2004 · Journal of Clinical Gastroenterology

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

GOALS: To estimate the direct medical costs associated with chronic hepatitis B (CHB) infection in the United States. BACKGROUND: Approximately 240,000 new cases of hepatitis B infection occur annually in the United States. There are estimated to be 1.25 million sufferers of CHB in the United States. However, the economic impact of these infections has not been well studied. STUDY: We conducted a retrospective cohort analysis using administrative healthcare claims data to estimate costs for six health states associated with CHB infection. The six states were as follows: 1) CHB, 2) compensated cirrhosis, 3) decompensated cirrhosis, 4) liver transplantation, 5) transplant care >12 months following transplant, and 6) hepatocellular carcinoma. Patients in each health state were identified using diagnostic and procedure codes, and their utilization was tracked during their time in that health state. To estimate costs, we used reimbursed amounts and adjusted to year US 2000 dollars. RESULTS: Average annual costs for patients in each health state were as follows: CHB, US 761 dollars; compensated cirrhosis, US 227 dollars; decompensated cirrhosis, US 11,459 dollars; liver transplant, US 86,552 dollars; transplant care >12 months following transplant, US 12,560 dollars; and hepatocellular carcinoma, US 7,533 dollars. Medications contributed the largest proportion of costs in CHB and compensated cirrhosis disease states, while hospitalizations were the largest cost component in the other health states. CONCLUSIONS: This analysis provides estimates of the annual costs of complications of hepatitis B infection in the United States. The most progressive health states were associated with significantly higher costs.

Overview

Integrity signals

Registry

Crossref · 10.1097/00004836-200411003-00005

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 6 references

Research works printed but not linked: 1

  1. Brooks, 2001, Am J Manag Care, 7, 677

Cited by

See all 57

Metadata

Authors
Lee, T. A., Veenstra, D. L., Iloeje, U. H., & Sullivan, S. D.
Affiliations
  • Northwestern University (US)
  • University of Washington (US)
  • Bristol-Myers Squibb (United States) (US)
Corresponding author
Lee, Todd A.
Venue
Journal of Clinical Gastroenterology
Published
2004-11
Volume
38
Issue
10 Suppl 3
Pages
S144-S147
ISSN
0192-0790 (ISSN-L)
OpenAlex
W2011794322
Cited by
57
References
6
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2020: 3 · 2018: 4 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 1 · 2013: 1 · 2012: 5
FWCI
1.20
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Keywords
chronic hepatitis B, direct medical costs, liver cirrhosis, decompensated cirrhosis, liver transplantation, transplant care, hepatocellular carcinoma, hospital costs, drug costs, economic burden of disease
MeSH terms
Costs and Cost Analysis, Humans, Middle Aged, Retrospective Studies, United States, Cohort Studies, Health Care Costs, Hepatitis B, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost of Chronic Hepatitis B Infection in the United States. https://app.cochat.ai/papers/10.1097/00004836-200411003-00005
The paper
Lee, T. A., Veenstra, D. L., Iloeje, U. H., & Sullivan, S. D. (2004). Cost of Chronic Hepatitis B Infection in the United States. Journal of Clinical Gastroenterology. https://doi.org/10.1097/00004836-200411003-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.